Full Press Release Details
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46thAnnual Healthcare Conference on Monday, March 2, 2026 at 9:10 am ET.
A live audio webcast of the presentation will be available on the Investors section of the Company’s website,www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on itsAlnylam 2030strategy to accelerate innovation and scale impact to transform human health. For more information, please visitwww.alnylam.comor follow Alnylam onX,LinkedIn,Facebook,Instagram, orYouTube.